«You can look at it in terms of
tumor biology — our current strategy is to treat and then as long as the
tumor responds to any degree, to watch for
progression without paying much attention to depth of response.
Researchers say that patients whose
tumors have high levels of PD - L1, a protein linked to increased risk of the disease, had longer survival to chemotherapy
without progression of the disease.